{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:49:17Z","timestamp":1773751757710,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.diagmicrobio.2014.09.006","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T06:18:24Z","timestamp":1410848304000},"page":"294-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of Etests and Vitek 2\u00ae to broth microdilution for the susceptibility testing of Cryptococcus neoformans"],"prefix":"10.1016","volume":"80","author":[{"given":"Yesholata","family":"Mahabeer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianithi","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afton","family":"Dorasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thumbi","family":"Ndung\u2019u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed-Yunus","family":"Moosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martyn","family":"French","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koleka","family":"Mlisana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yacoob","family":"Coovadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0125","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/jac\/46.6.997","article-title":"Comparison of the Etest & microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents","volume":"46","author":"Aller","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0065","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/AAC.44.6.1544-1548.2000","article-title":"Correlation of fluconazole MICs with clinical outcome in cryptococcal infection","volume":"44","author":"Aller","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.riam.2009.02.001","article-title":"Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy","volume":"26","author":"Arechavala","year":"2009","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0075","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/507895","article-title":"Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution","volume":"43","author":"Bicanic","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0095","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/infdis\/174.4.812","article-title":"Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated cryptococcosis","volume":"174","author":"Brandt","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0020","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0090","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1128\/AAC.37.6.1383","article-title":"Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole","volume":"37","author":"Casadevall","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb9100","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1097\/QAD.0b013e3283614a8d","article-title":"Clinical and mycological predictors predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome","volume":"27","author":"Chang","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0105","series-title":"CLSI document M27\u20133A","article-title":"Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard - third edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0015","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/339540","article-title":"Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus","volume":"34","author":"Corbett","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0120","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1128\/JCM.02316-09","volume":"48","author":"Cuenca-Estrella","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0170","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1128\/AAC.01520-05","article-title":"Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis","volume":"50","author":"Dannaoui","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0030","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","author":"Day","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0145","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1128\/AAC.01115-12","article-title":"Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint and epidemiological cutoff values for values for fluconazole, itraconazole, posaconazole, and voriconazole","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0140","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.06252-11","article-title":"Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint and epidemiological cutoff values for amphotericin b and flucytosine","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0080","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1097\/00002030-200111230-00026","article-title":"Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease","volume":"15","author":"Friese","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0135","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3109\/13693780903473343","article-title":"Evaluation of the VITEK 2 system to test the susceptibility of Candida spp., Trichosporon asahii and Cryptococcus neoformans to amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27\u2013A3 reference method","volume":"48","author":"Gonz\u00e1lez","year":"2010","journal-title":"Med Mycol"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0100","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/AAC.00048-11","article-title":"Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002\u20132003 and 2007\u20132008","volume":"55","author":"Govender","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0035","article-title":"Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update","author":"Govender","year":"2013","journal-title":"S Afr J HIV Med"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2334-10-67","article-title":"Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases","volume":"10","author":"Jarvis","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0070","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2334-12-361","article-title":"Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis","volume":"12","author":"Lee","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0115","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.47.5.1647-1651.2003","article-title":"Correlation between E-Test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole","volume":"47","author":"Matar","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1128\/JCM.41.1.97-99.2003","article-title":"Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans","volume":"41","author":"Maxwell","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0055","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0160","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1128\/JCM.36.9.2586-2589.1998","article-title":"Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media","volume":"36","author":"Pfaller","year":"1998","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1128\/AAC.43.1.169","article-title":"In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa","volume":"43","author":"Pfaller","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0040","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JCM.43.5.2163-2167.2005","article-title":"Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0110","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1128\/JCM.00403-07","article-title":"Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp","volume":"45","author":"Pfaller","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/JCM.01747-08","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0175","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF01708563","article-title":"Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the Etest","volume":"16","author":"Simor","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0165","doi-asserted-by":"crossref","DOI":"10.1007\/s11046-012-9528-9","article-title":"Comparative Analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of Cryptococcus neoformans","author":"Tewari","year":"2012","journal-title":"Mycopathologia"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome","volume":"337","author":"Van der Horst","year":"1997","journal-title":"NEJM"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2014.09.006_bb0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1179\/joc.2003.15.2.124","article-title":"Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?","volume":"15","author":"Viviani","year":"2003","journal-title":"J Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jac\/42.3.321","article-title":"Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans","volume":"42","author":"Warnock","year":"1998","journal-title":"J Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0060","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/clinids\/22.2.322","article-title":"Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of anti-fungal susceptibility testing","volume":"22","author":"Witt","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0050","doi-asserted-by":"crossref","DOI":"10.3109\/13693786.2011.554893","article-title":"Voriconazole: may be an option for treatment of cryptococcal meningitis","author":"Yong","year":"2011","journal-title":"Med Mycol"},{"key":"10.1016\/j.diagmicrobio.2014.09.006_bb0155","series-title":"45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 16\u201319 December 2005, Poster M-1619","article-title":"Rapid antifungal susceptibility testing of medically important yeasts with the Vitek\u00ae 2 Systems","author":"Zambardi","year":"2005"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931400368X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931400368X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T12:33:08Z","timestamp":1598272388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288931400368X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S073288931400368X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.09.006","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Etests and Vitek 2\u00ae to broth microdilution for the susceptibility testing of Cryptococcus neoformans","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}